SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-24-001290 to KAZIA THERAPEUTICS LTD (KZIA) (CIK 0001075880) (KZIA)

KAZIA THERAPEUTICS LTD (KZIA) (CIK 0001075880)
Date: Feb. 1, 2024 · CIK: 0001075880 · Accession: 0000000000-24-001290

AI Filing Summary & Sentiment

File numbers found in text: 333-276774

Date
February 1, 2024
Author
Not clearly detected
Form
UPLOAD
Company
KAZIA THERAPEUTICS LTD (KZIA) (CIK 0001075880)

Letter

United States securities and exchange commission logo February 1, 2024 John Friend, M.D. Chief Executive Officer Kazia Therapeutics Limited Three International Towers Level 24 300 Barangaroo Avenue Sydney, NSW, 2000, Australia Re:Kazia Therapeutics Limited Registration Statement on Form F-1 Filed January 31, 2024 File No. 333-276774 Dear John Friend: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Stephanie Richards, Esq.

Show Raw Text
United States securities and exchange commission logo
February 1, 2024
John Friend, M.D.
Chief Executive Officer
Kazia Therapeutics Limited
Three International Towers Level 24
300 Barangaroo Avenue
Sydney, NSW, 2000, Australia
Re:Kazia Therapeutics Limited
Registration Statement on Form F-1
Filed January 31, 2024
File No. 333-276774
Dear John Friend:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Stephanie Richards, Esq.